Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of her2 status in breast cancer

Aaron S. Mansfield, William R. Sukov, Jeanette E. Eckel-Passow, Yuta Sakai, Frank J. Walsh, Melissa Lonzo, Anne E. Wiktor, Ahmet M Dogan, Robert B. Jenkins

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

The determination of HER2 amplification is critical to selecting appropriate patients for HER2 targeted therapy in breast cancer. Dual in situ hybridization (DISH), an alternative to fluorescence in situ hybridization (FISH) and immunohistochemistry, is now available. To compare the FISH and DISH methods, we tested 251 samples enriched for common or difficult-to-assess HER2 anomalies. Seven samples failed DISH testing. There was a 64% (156/244) concordance between FISH and DISH by anomaly (? = 0.58, 95% confidence interval, 0.51-0.65; P < .0001) and an 83% (203/244) concordance by amplification status (k = 0.58; 95% confidence interval, 0.47-0.69; P < .0001). DISH resulted in lower estimates of HER2/ centromere 17 ratios than FISH, and many cases that were equivocal with FISH were normal with DISH. DISH did not detect any case with coamplification of HER2 and centromere 17. Using a cohort of difficult specimens, we observed less than 95% concordance between FISH and DISH. DISH may underestimate the HER2/chromosome 17 ratio, or FISH may overestimate this ratio.

Original languageEnglish (US)
Pages (from-to)144-150
Number of pages7
JournalAmerican journal of clinical pathology
Volume139
Issue number2
DOIs
StatePublished - Feb 1 2013

Keywords

  • Breast cancer
  • HER2
  • In situ hybridization

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of her2 status in breast cancer'. Together they form a unique fingerprint.

  • Cite this